PO.ET05.02 · 实验与分子治疗
Antitumor effect of TROP2-targeted antibody drug conjugate, datopotamab deruxtecan (Dato-DXd), in association with DNA damage response in breast cancer cell lines
作者与单位
摘要 Abstract
Background: Trophoblast cell surface antigen-2 (TROP2), Tumor-associated calcium signal transducer 2 (TACSTD2) is a transmembrane glycoprotein expressed in various cancer types. Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) composed of an anti-TROP2 antibody (Datopotamab) linked via a cleavable peptide linker to DXd, a Topoisomerase-I inhibitor. Topoisomerase-I maintains DNA topological stress by resolving DNA supercoils during replication and transcription. We sought to determine whether this DNA damage mechanism classically induced by topoisomerase I inhibitors emerges when delivered through an ADC, and to further elucidate the previously uncharacterized molecular mechanisms of DNA damage response (DDR) and cell death by Dato-DXd.
Methods: Five established human breast cancer cell lines and one patient-derived breast cancer (PDC) cell line (SNU-3171) were used in this study. MCF7 and SNU-3171 were luminal breast cancer cell lines, and the others were triple-negative breast cancer (TNBC) cell lines. Sensitivity of each cell to Dato-DXd was assessed by colony formation assay (CFA) for 14 days (0.25-5 nM). Internalization and cell cycle analysis were performed by flow cytometry. Apoptosis was detected by Annexin V assay. The protein expression of TROP2, DNA damage, and repair molecules was analyzed by Western blotting and immunofluorescence.
Results: Based on CFA results, HCC1806, HCC70, and SNU-3171 were identified as sensitive cells (IC 50 <0.5 nM), whereas MCF7, MDA-MB-157, and HCC1395 as less sensitive cells (IC 50 >2.5 nM) to Dato-DXd. Dato-DXd was internalized within 2 hours in TROP2-positive cells. Following internalization, topoisomerase-I cleavage complexes (Top1ccs) were formed in all TROP2-positive cells; however, co-localization of Top1ccs and ɣ-H2AX was observed only in sensitive cells. Dato-DXd induced G2/M arrest in all TROP2-positive cells. In sensitive cells, the expression of TDP1, XRCC1, DNA Ligase III, and PNKP was decreased, while phospho-Chk1 (S345) and ɣ-H2AX were increased, indicating a reduction in single-strand DNA damage repair capacity and activation of DDR. Moreover, increased doses of Dato-DXd were associated with higher number of Annexin V-positive cells and sub-G1 populations, as well as higher expression of cleaved PARP, caspase-3, and caspase-7 in sensitive cells.
Conclusion: Dato-DXd demonstrated efficient internalization in TROP2-positive breast cancer cells including PDC, and impaired DNA single-strand break (SSB) repair, which consequently induce apoptosis in sensitive breast cancer cells. In particular, formation of Top1ccs and G2/M phase accumulation are induced in most of TROP2-positive cells. Further experiments are required to elucidate how impaired SSB repair contributes to the induction of DNA double-strand breaks and apoptosis.
利益披露 Disclosure
S. Lim, None..
S. Ham, None..
H. Hwang, None..
Y. Noh, None.
J. Koh,
AstraZeneza Other, Consulting fees.
C. Lee, None..
M. Jeong, None..
Y. Kim, None..
M. Lee, None..
S. Kim, None..
C. Park, None..
D. Lee, None.
K. Lee,
Roche ).
AstraZeneca Other, reported honoraria.
Eisai Other, reported honoraria.
Lilly Other, reported honoraria.
Novartis Other, reported honoraria.
Roche Other, reported honoraria.
Pfizer Other, reported honoraria.
S. Im,
Daiichi Sankyo ), Other, Consulting fees.
AstraZeneca ), Other, Consulting fees.
Eisai ), Other, Consulting fees.
Daewoong Pharm ).
Pfizer ), Consulting fees.
Roche ), Other, Consulting fees.
Boryung Pharm ).
Hanmi Other, Consulting fees.
Lilly Other, Consulting fees.
MSD Other, Consulting fees.
Idience Other, Consulting fees.
Norvatis Other, Consulting fees.
GSK Other, Consulting fees.
Bertis Other, Consulting fees.